---
title: "Xarelto (rivaroxaban), all indications: Specific populations questions"
description: "Specific populations questions on Xarelto (rivaroxaban) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Xarelto be used during pregnancy? Can Xarelto be used while breastfeeding? Is Xarelto safe and effective for adults 65 and older? Can Xarelto be used with liver impairment? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban), all indications: Specific populations questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)  
Indication pages: [Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)

## Pregnancy and breastfeeding

<a id="xarelto-pregnancy"></a>

### Can Xarelto be used during pregnancy?

> “The limited available data on XARELTO in pregnant women are insufficient to 
> inform a drug-associated risk of adverse developmental outcomes. Use XARELTO 
> with caution in pregnant patients because of the potential for pregnancy related 
> hemorrhage and/or emergent delivery. The anticoagulant effect of XARELTO cannot 
> be reliably monitored with standard laboratory testing. Consider the benefits and 
> risks of XARELTO for the mother and possible risks to the fetus when prescribing 
> XARELTO to a pregnant woman [see Warnings and Precautions (5.2, 5.7)].”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

<a id="xarelto-breastfeeding"></a>

### Can Xarelto be used while breastfeeding?

> “Rivaroxaban has been detected in human milk. There are insufficient data to 
> determine the effects of rivaroxaban on the breastfed child or on milk 
> production. Rivaroxaban and/or its metabolites were present in the milk of rats. 
> The developmental and health benefits of breastfeeding should be considered 
> along with the mother’s clinical need for XARELTO and any potential adverse 
> effects on the breastfed infant from XARELTO or from the underlying maternal 
> condition (see Data).”

Source: [XARELTO: Prescribing information, page 11, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=11)

## Specific populations

<a id="xarelto-older-adults"></a>

### Is Xarelto safe and effective for adults 65 and older?

> “Of the total number of adult patients in clinical trials for the approved indications 
> of XARELTO (N=64,943 patients), 64 percent were 65 years and over, with 
> 27 percent 75 years and over. In clinical trials the efficacy of XARELTO in the 
> elderly (65 years or older) was similar to that seen in patients younger than 
> 65 years. Both thrombotic and bleeding event rates were higher in these older 
> patients [see Clinical Pharmacology (12.3) and Clinical Studies (14)].”

Source: [XARELTO: Prescribing information, page 11, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=11)

Note: This passage covers adult patients in the trials for all approved indications.

<a id="xarelto-liver"></a>

### Can Xarelto be used with liver impairment?

> “In a pharmacokinetic study, compared to healthy adult subjects with normal liver 
> function, AUC increases of 127% were observed in adult subjects with moderate 
> hepatic impairment (Child-Pugh B).
> The safety or PK of XARELTO in patients with severe hepatic impairment (Child-
> Pugh C) has not been evaluated [see Clinical Pharmacology (12.3)].
> Avoid the use of XARELTO in patients with moderate (Child-Pugh B) and severe 
> (Child-Pugh C) hepatic impairment or with any hepatic disease associated with 
> coagulopathy.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

## Related pages
- [Medical information: Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto)
- [Indication](https://www.evicenter.com/medical-information/xarelto/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xarelto/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/xarelto/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/xarelto/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xarelto/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto/access-and-coverage)
